Pfizer Inc. and BioNTech SE have announced that initial lab studies show a third dose of their Covid-19 vaccine neutralizes the Omicron variant. These results come as great news amid fears of a new ...

Pfizer and BioNTech have submitted a request to the FDA for Emergency Use Authorization of an omicron-adapted COVID-19 booster dose for individuals 12 years of age and older. Pending authorization, ...

Preclinical data showed a booster dose of Pfizer and BioNTech's Omicron BA.4/BA.5-adapted bivalent vaccine generated a strong neutralizing antibody response against Omicron BA.1, BA.2 and BA.4/BA.5 ...

Pfizer and BioNTech have asked the Food and Drug Administration for emergency use authorization of their COVID-19 booster targeting omicron subvariants BA.4 and BA.5 and the original strain of the ...

Pfizer and BioNTech said Wednesday that initial lab tests show that the omicron variant partly escapes protection offered by the companies' two-dose regimen of their COVID-19 vaccine. However, those ...

The updated COVID-19 vaccine is tailored to the KP.2 strain of the SARS-CoV-2 Omicron JN.1 lineage and is recommended for individuals 6 months of age and older The KP.2 adaptation is based on FDA ...

If COVID-19 booster shots become an annual precaution, the same way we get a flu shot every year, the next one may be formulated differently. Moderna and Pfizer working on a bivalent vaccine that ...

Pfizer and BioNTech said Tuesday they've begun clinical trials for an omicron-based COVID-19 vaccine. According to a press release, the vaccine will be tested initially in adults aged 18 to 55. "While ...

Pfizer’s booster provides a much stronger immune response against the omicron variant than its two-shot series, according to the results of two recent studies. The University of Oxford released ...

NEW YORK (WABC) -- Pfizer and BioNTech say if a variant that evades the vaccine emerges, they would be ready to produce a tailor-made shot against that new variant within about 100 days. The companies ...